High flow nasal cannula oxygen therapy in adults with COVID-19 respiratory failure. A case report

Vasileios Karamouzos¹, Fotini Fligou¹, Charalambos Gogos², Dimitrios Velissaris²

¹Intensive Care Unit, University Hospital of Patras, Rion; ²Internal Medicine Department, University Hospital of Patras, Rion, Greece

Abstract

The novel corona virus (SARS-CoV-2) continuous to spread around the globe causing high mortality, tremendous stress on healthcare systems and an unprecedented disruption of everyday life with unpredictable socioeconomic ramifications. The disease is typically affecting the respiratory system and some patients will develop refractory hypoxemic respiratory insufficiency requiring mechanical ventilation. The role of non-invasive ventilation (NIV), high flow nasal cannula (HFNC) or continuous positive airway pressure devices (C-PAP) in the treatment of the 2019 corona virus disease (COVID-19) is not yet clear. We hereby report a case of a 44-year-old COVID-19 positive male patient suffering from hypoxic respiratory failure that was successfully treated with high flow nasal cannula oxygen therapy in a negative pressure intensive care room. Although specific criteria for the use of high flow nasal canula devices in COVID-19 are not available at this time, clinicians could use this non-invasive modality as an alternative method of respiratory support in selected patients presenting with respiratory failure.

Introduction

Following the outbreak of the novel coronavirus (SARS-CoV-2) last year in China, the virus has spread globally in more than 170 countries forcing the World Health Organization to declare a pandemic. More than two million confirmed cases were registered by April 16, 2020 raising the death toll from the 2019 novel coronavirus disease (COVID-19) over 130000. The clinical presentation of patients suffering from CoVid-19 can vary from asymptomatic to severe disease with multiorgan failure and commonly reported symptoms include fever, non-productive cough, shortness of breath, myalgia, and fatigue [1]. The main target of the virus is the respiratory system and some patients in the course of the disease will develop refractory hypoxemic respiratory insufficiency requiring mechanical ventilation. The role of non-invasive ventilation (NIV), high flow nasal cannula (HFNC) or continuous positive airway pressure devices (C-PAP) in the treatment of medium to severe Adult Respiratory Distress Syndrome (ARDS) from COVID-19 is not yet clear. Furthermore, health care safety issues are raised since virus dispersion may increase using high flow devices [2]. In this report we present a patient suffering from moderate ARDS due to COVID-19 that was successfully discharged from a negative pressure Intensive Care Unit (ICU) after treatment with HNFC.

Case Report

A 44-year-old male with a past medical history of hypertension controlled by angiotensin II receptor antagonist (valsartan 80 mg qd) was admitted to the Emergency Department (ED) of a tertiary referral hospital in south-west Greece due to fever and mild respiratory distress. On admission the patient was alert, orientated and hemodynamically stable. He complained of a non-productive cough accompanied by mild dyspnea on exertion and his axillary temperature was 38.3°C. Arterial blood gas (ABG) analysis on room air confirmed hypoxemia (PH = 7.42; PO₂ - 63 mmHg; PCO₂ - 36 mmHg; HCO₃ - 22.5; BE = -1.5) and chest aus-
Cultivation revealed some crackles on the lower lobe of the right lung. No significant findings were noticed from the rest of the physical examination and his chest X-ray on admission was unremarkable (Figure 1). Epidemiological anamnesis revealed that the patient had recently returned from a pilgrimage to the Middle East where COVID-19 cases were reported. A respiratory specimen was obtained and he was transferred to an isolated room in the Internal Medicine Department where he was treated with supplemental oxygen via nasal cannula (3 l/min), Ceftriaxone (2 gr i.v. qd), Azithromycin (500 mg i.v. qd), and Oseltamivir (75 mg p.o. bid). The test for SARS-CoV-2 returned positive and a combination of lopinavir/ritonavir (400 mg/100 mg p.o. bid) and hydroxychloroquine (200 mg p.o. bid) were added to the treatment regimen.

On day 6 the patient’s respiratory function suddenly deteriorated. He was treated with a Venturi face mask (60% FiO₂) and his PaO₂/FiO₂ ratio was 110. Blood gas analysis revealed hypoxemia and respiratory alkalosis (\( \text{PH} = 7.46; \text{PO}_2 = 66 \text{ mmHg}; \text{PCO}_2 = 33 \text{ mmHg}; \text{HCO}_3 = 22.7; \text{BE} = -0.8 \)) and a chest CT scan showed extended scattered ground glass lesions in both lungs (Figures 2 and 3). Due to the significant deterioration of the patient’s respiratory function he was transferred to a negative pressure isolation ICU room. The patient was alert, hemodynamically stable and a HFNC oxygen therapy trial was attempted. Initial FiO₂ concentration and flow rate was 100% and 30 l/min, respectively. The flow rate was gradually increased to 60 l/min and the FiO₂ concentration was reduced to 60%. The patient responded well to treatment, his PaO₂/FiO₂ ratio was 150 and it was decided to remain in HFNC therapy under close monitoring. The following days he remained stable and was instructed with the help of the physiotherapist to turn into the prone position three times a day leading to slow but progressive improvement of the oxygenation, and respiratory status. His PaO₂/FiO₂ ratio further increased above 250 and after 10 days he was successfully weaned from HFNC and was transferred to the internal medicine department.

**Discussion**

SARS-CoV-2 is a positive-sense RNA virus, member of the coronavirus family, with a transmissibility similar to other respiratory viruses via large droplet transmission. Upon entering the host’s organism, the virus binds to angiotensin-converting enzyme 2 (ACE 2) receptor on type II alveolar cells and intestinal epithelia, infiltrates the cell and starts replication. The main clinical findings include fever, upper and lower respiratory symptoms such as dyspnea, constitutional symptoms, and less commonly gastrointestinal symptoms (up to 10%). Physical examination is generally non-specific. The typical disease course consists of an incubation period of 4 to 14 days; in severe cases, dyspnea is recognized around 6 days post exposure, admission to Hospital after 8 days and ICU admission after 10 days post exposure [1,3].
Patients suffering from COVID-19 require oxygen therapy due to type 1 respiratory failure and as the disease progresses a difficult choice must be made between invasive and non-invasive ventilation. Nowadays a variety of different non-invasive systems with different patient interfaces offer us a multitude of therapeutic options. High-flow nasal cannula (HFNC) is a type of non-invasive oxygen therapy capable of delivering heated and humidified air-oxygen mixtures at 0.21 to 1 FiO₂ and at flow rates up to 60 l/min. HFNC is considered to have important physiological effects, such as reduction of patient’s anatomical dead space, a PEEP effect and a constant fraction of inspired oxygen. Recently has gained a position in the field of respiratory support for critically ill adult patients as clinicians apply HFNC oxygen in a variety of situations, like hypoxic respiratory failure, acute exacerbation of chronic obstructive pulmonary disease (COPD), post-extubation, pre-intubation, and to patients with end stage status. In regard to COVID-19, the true incidence of hypoxic respiratory failure is not clear, it seems, however, that about 14% of cases will develop severe dis-

fection, and 5% will require finally ICU admission and mechanical ventilation [4].

According to Surviving Sepsis Campaign (SSC) guidelines for the management of critically ill adults with COVID-19, in cases presenting with acute hypoxic respiratory failure despite the conventional oxygen therapy, there is a weak recommendation for using HFNC over conventional oxygen therapy [5]. A systematic review and meta-analysis of 9 RCTs with 2,093 patients showed that the use of HFNC reduced the intubation rate compared to conventional oxygen therapy, but did not affect the risk of death or ICU length of stay [6-8]. In the COVID-19 pandemic, however, a possible reduction in intubation rate is crucial as medical resources worldwide are limited. Furthermore, the use of HFNC was better tolerated by the patients as they find it more comfortable in comparison to conventional oxygen therapy [9].

Comparing HNFC to NIV, SSC guidelines also recommend the use of HFNC over non-invasive positive pressure ventilation (NIPPV)(weak recommendation, LOE) [5]. A RCT comparing the two settings in patients with acute hypoxic respiratory failure, showed that HFNC resulted in reduced mortality at 90 days but did not significantly reduced the need for intubation, and a meta-analysis showed that HFNC decreased the need for intubation, yet without significantly reducing mortality or ICU length of stay [6,9]. Similar to conventional oxygen therapy, patients found HFNC more comfortable than NIPPV [9].

Most of the knowledge accumulated referring to the use of HFNC in respiratory tract viral infections is from patients with H1N1 influenza virus and SARS-CoV-1/MERS-CoV corona viruses. The experience of HFNC in patients with severe acute respiratory infection (SARI) has been described in a cohort of ICU patients admitted with SARI due to 2009 H1N1 Influenza A in a study by Rello et al. HFNC appeared to be an innovative and effective modality for the early treatment of adults with SARI [10]. Finally a recent small trial from China showed that from a total of 17 patients treated with HNFC, 7 (41%) experienced treatment failure and among patients with PO₂/FiO₂ </200 failure rates reached 63% [11].

Observational studies in patients with bacterial pneumonia, propose that HFNC does not seem to confer an increased risk of transmission of disease and the risk of bacterial environmental contamination is similar to that of conventional oxygen [12]. In patients with SARS treated with non-invasive methods the risk of transmission may be greater. Fowler et al. showed that nurses caring for patients with SARS receiving noninvasive positive-pressure ventilation may be at an increased risk (RR, 2.33; 95% CI, 0.25 to 21.76; p=0.5) and the SSC guidelines suggests that all aerosol-generating procedures should be performed in a negative pressure room [5,13]. In any case patients receiving HFNC should be in a negative pressure room for maximum personnel safety and closely monitored in a setting where intubation can be facilitated immediately in the event of decompensation.

In our case, we decided to try a non-invasive modality due to the patient’s single system involvement. Decisive factors in choosing HNFC over NIV/CPAP therapy were the fact that our patient was suffering from respiratory failure type I and the tolerability profile of HFNC. As previously reported, awake prone positioning can significantly improve oxygenation and pulmonary heterogeneity [14]. HFNC allowed our patient to turn into the prone position 3 times a day, a maneuver which also helped in improving oxygenation.

Conclusions

HFNC oxygen delivery could be an additional option and should be available in our armamentarium as an alternative method of respiratory support in patients suffering from COVID-19. Although specific criteria for commencing or stopping HFNC therapy are not available at this time, clinicians could use this non-invasive modality in selected COVID-19 patients suffering from respiratory failure.

References

8. Rochwerger B, Granton D, Wang DX, et al. High flow nasal cannula compared with conventional oxygen therapy for acute...